Status:
TERMINATED
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Lead Sponsor:
Pfizer
Conditions:
Gastrointestinal Stromal Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5 mg daily or i...
Detailed Description
The study prematurely discontinued on July 27, 2009 due to poor recruitment and operational futility as a result of changes in clinical practice. There were no safety or efficacy concerns regarding th...
Eligibility Criteria
Inclusion
- Patients with gastrointestinal stromal tumors whose disease has progressed on imatinib 400 mg daily.
Exclusion
- Current treatment with any chemotherapy other than imatinib.
- Current treatment with any dose of imatinib other than 400 mg
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT00372567
Start Date
June 1 2007
End Date
November 1 2009
Last Update
March 17 2011
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Detroit, Michigan, United States, 48201
2
Pfizer Investigational Site
Farmington Hills, Michigan, United States, 48334
3
Pfizer Investigational Site
City of Saint Peters, Missouri, United States, 63376
4
Pfizer Investigational Site
Creve Coeur, Missouri, United States, 63141